A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Study Name | |
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | |
ClinicalTrials.gov Identifier (if applicable) | |
NCT05849480 | |
Clinical Trial Category (check all that apply) | |
|
|
Study Center | |
Institution Name | |
National Cancer Institute | |
City | |
Bethesda | |
State | |
Maryland | |
Zip Code | |
20892 | |
Country | |
United States | |
Website | |
https://ccr.cancer.gov | |
Study Contacts | |
Principal Investigator | |
Cecilia Monge | |
P.I. Phone | |
(240) 858-3603 | |
P.I. Email | |
cecilia.mongebonilla@nih.gov | |
List additional Principal Investigators (include phone number and email) | |
Tim Greten (240) 760 6114 tim.greten@nih.gov |
|
Study Coordinator | |
Donna Mabry Hrones | |
Study Coordinator Phone | |
(240) 858-3155 | |
Study Coordinator Email | |
donna.mabry@nih.gov | |
OVERVIEW – in layman’s terms (150 words max) | |
In this study we test the combination of two different immunotherapy drugs (anti-CD40 and anti-PD1) in combination with chemotherapy (capecitabine and oxaliplatin (CAPOX). This study is being offered to all patients who failed first-line treatment or refused first-line therapy. The study concept and preclinical data has been supported by the CCF. | |
Enrollment | |
26 | |
Study Start Date | |
03/27/2024 | |
Estimated Completion Date | |
03/31/2025 | |
Purpose of the Study – in Layman’s Terms (use the “+” to add more list items) | |
|
|
Inclusion Criteria – Patients Must: | |
|
|
Exclusion Criteria – Patients Must NOT: | |
|
|
REQUIRED TESTS PRIOR TO BEGINNING STUDY TREATMENT – in layman’s terms | |
|
|
POTENTIAL SIDE-EFFECTS – in layman’s terms | |
|
|
Financial Assistance is available to participants for travel, lodging, etc. | |
|